Weak churn signals a softer labor market

GLP-1 weight-loss drug injections have slimmed many waistlines and wallets. U.S. regulators have now approved a much less expensive alternative; Novo Nordisk has gotten the green light for an oral version of Wegovy. Pills are cheaper to manufacture than injectables, and that could be a game-changer. Then, consumers still feel pessimistic heading into the new year, and more Americans are staying unemployed for longer.